SciBase has reached a significant milestone with over 300,000 Nevisense tests performed worldwide, marking a growing shift toward advanced diagnostic technologies in dermatology. Nevisense is the only FDA-approved and CE-marked non-invasive melanoma detection system, designed to support dermatologists in evaluating suspicious moles with greater precision. By measuring the electrical properties of skin tissue, Nevisense delivers objective, real-time data that augments traditional dermoscopy, enabling a more accurate assessment of a patient’s risk of melanoma at the point of care.

This innovation plays a critical role in addressing the global burden of melanoma, which continues to rise across many populations. Early and accurate detection is essential for improving survival rates, and Nevisense helps fill a vital gap by reducing reliance on subjective visual assessments alone. With over 60 peer-reviewed studies validating its performance, the technology is gaining recognition for improving diagnostic accuracy, supporting more informed biopsy decisions, and minimizing unnecessary procedures—leading to more efficient use of healthcare resources.

The milestone of 300,000 patients tested underscores Nevisense’s growing clinical relevance and real-world impact. Dermatologists worldwide are leveraging this AI-powered tool to make earlier, more confident diagnoses, which can ultimately lead to better outcomes for patients. As personalized medicine and precision diagnostics become central to modern healthcare, Nevisense stands out as a practical, evidence-based solution helping to elevate the standard of care in skin cancer detection.

MedTech Spectrum's Summary

Milestone Achievement: Over 300,000 patients have been tested with Nevisense, reflecting its growing adoption as a trusted tool in melanoma detection.

Clinical Value: Nevisense enhances diagnostic accuracy and supports early, non-invasive melanoma detection, helping reduce unnecessary biopsies and improve patient outcomes.

Global Impact: As melanoma rates rise, Nevisense provides dermatologists with AI-supported, real-time data to make personalized, risk-aligned decisions—contributing to better healthcare efficiency and patient care worldwide.